Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma [Yahoo! Finance]
Marker Therapeutics Announces $16.1 Million Private Placement [Yahoo! Finance]
Marker Therapeutics Announces $16.1 Million Private Placement
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer [Yahoo! Finance]